What is Reflux?
Reflux is the backflow of acid from the stomach into the gullet (“foodpipe”) which may become inflamed and painful. This may cause you symptoms such as a painful sensation in the chest rising up to your throat (heartburn) and a sour taste in the mouth (acid regurgitation).
Do I get instant relief from taking a Nexium tablet?
Nexium Control is not meant to bring immediate relief. You may need to take the tablets for 2-3 days in a row before you feel better. You must talk to a doctor if you do not feel better or if you feel worse after 14 days.
How much to take• The recommended dose is one tablet a day. • Do not take more than this recommended dose of one tablet (20 mg) a day, even if you don’t feel an improvement immediately. • You may need to take the tablets for 2 or 3 days in a row before your reflux symptoms (for example, heartburn and acid regurgitation) get better. • The treatment length is up to 14 days. • When your reflux symptoms have completely gone you should stop taking this medicine. • If your reflux symptoms get worse or do not improve after taking this medicine for 14 days in a row, you should consult a doctor. If you have persistent or longstanding, frequently recurring symptoms even after treatment with this medicine, you should contact your doctor. Taking this medicine • You can take your tablet at any time of the day either with food or on an empty stomach. • Swallow your tablet whole with half a glass of water. Do not chew or crush the tablet. This is because the tablet contains coated pellets, which stop the medicine from being broken down by the acid in your stomach. It is important not to damage the pellets.
Alternative method of taking this medicine• Put the tablet in a glass of still (non-fizzy) water. Do not use any other liquids. • Stir until the tablet breaks up (the mixture will not be clear) then drink the mixture straight away or within 30 minutes. Always stir the mixture just before drinking it. • To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of water and drink it. The solid pieces contain the medicine – do not chew or crush them
Please read the patient information leaflet above to get more information as to side effects, precautions of use etc.
Active Ingredients:
Each gastro-resistant tablet contains 20 mg esomeprazole (as magnesium trihydrate)
List of Excipients:
Glycerol monostearate 40-55 HydroxypropylcelluloseHypromellose 2910 (6 mPa-s) Reddish-brown iron oxide (E-172) Yellow iron oxide (E-172)Magnesium stearate Methacrylic acid ethylacrylate copolymer (1: 1) dispersion 30 per cent Cellulose microcrystallineSynthetic Paraffin Macrogol 6000Polysorbate 80 Crospovidone (Type A) Sodium stearyl fumarateSugar spheres (sucrose and maize starch), Talc, Titanium dioxide (E-171) Triethyl citrate
The manufacturer’s patient information leaflet contains a detailed summary of the excipients which includes more details on the symptoms, how to use, and what to expect when using this product. You can also read more about the symptoms and usage information in the manufacturer’s patient information leaflet.
Nexium ControlThe following information is included to provide additional information to the summary of excipients.
Nexium Control 20 mg film-coated tablets
When taking esomeprazole, you should always read the enclosed leaflet before taking any dose of the medicine. If you have any questions or concerns about this medicine, check the manufacturer’s patient information leaflet or the manufacturer’s information below.
To provide more information on the manufacturer’s patient information, please read this information leaflet carefully. You should always strictly follow it when taking esomeprazole.
AstraZeneca and Teva, the US-based global pharmaceutical company that develops and markets cancer drugs, have been in talks over a new US agreement to sell their own version of Nexium, a widely used heartburn drug that treats heartburn for more than 90 million people worldwide.
The US government has been keen on selling the drug to other countries for years but Teva is unlikely to follow suit and talks are still on the table.
The US drugmaker said Wednesday it would offer a "full-time" contract to supply Nexium for two years and will be willing to make Nexium on the back of a "full-line" agreement.
Nexium was invented by AstraZeneca and has been used to treat more than 100 conditions, including heartburn, ulcers and to treat high blood pressure.
But it was developed in the late 1990s by AstraZeneca's scientists, who developed the drug for heartburn in 2001. The company had hoped that the new drug would be as effective as Nexium and had no plans for any other drug, said AstraZeneca spokesman Ian Gordon.
Teva, the UK-based US-based company that develops cancer drugs, was also in talks over a deal with AstraZeneca last month, according to The Associated Press. "We are very pleased with this announcement," Teva spokesman Paul Whitaker told AP.
"We are very optimistic about this deal and are confident that we will be able to offer the best possible product."
The two companies have been in separate discussions over the past few months. The US government has been keen on selling the drug to other countries for years but Teva has been expected to make a new deal with AstraZeneca for two years.
The announcement comes as Teva is reopening a new cancer drug application process for its heartburn treatment, AstraZeneca said Wednesday.
Teva said the new Nexium, which it calls a "new version of Nexium," would be available to patients in Europe and Japan by the end of the year.
Under the terms of the deal, AstraZeneca is expected to sell Nexium on the back of a "full line" agreement and the US government will pay $50 million in a new government-run pharmaceutical research and development program.
The company said the new Nexium will be the first in a new class of heartburn drugs that treats the most common symptoms.
Teva spokeswoman Sarah Kirby said: "We are in the process of making this announcement and we will continue to work with our US partners on our approach to the deal."
The company also said that the US government would pay $25 million to resolve the case over a deal with Teva and that Teva would be free to sell Nexium in other countries as long as it remained on the patent.
The deal comes as a new drugmaker has launched a "full line" version of Nexium, which is expected to treat about 85 million people in the US and more than 90 million in Europe and Japan.
AstraZeneca spokesman Whitaker said: "The launch of the Nexium Nexium is expected to increase awareness and confidence around the drug for the vast majority of patients who have heartburn."
Teva said it had no plans to launch the Nexium on the back of a full line deal. But it added that Teva would be willing to make the Nexium on the back of a full line deal in the future.
The government is expected to offer the Nexium to doctors, hospitals and the public for up to two years and offer the drug in the US for a "full line" deal.
In response to questions from AP, Teva said it had agreed to pay $25 million to resolve the case.
The company said it would be willing to make a full line deal with AstraZeneca to supply Nexium in the US for a second year and the government would pay $50 million for a new government-run program to supply the drug.
AstraZeneca spokeswoman Kirby said: "We will continue to work with our US partners on the matter of the Nexium and will continue to provide the best possible product."
AstraZeneca spokesman Whitaker declined to comment.In this issue ofNephrology, Dr. Nadea says that she and a small group of doctors have been successful in prescribing esomeprazole (Nexium®) to prevent acid reflux. She notes that she was recently prescribed Nexium® for the reflux and ulcers that she was told are associated with the condition.
Dr. Nadea states that in recent years, the prevalence of GERD has increased, as people are more likely to smoke. She states that the number of people with GERD has decreased in the last 20 years and that the number of people who have had acid reflux has increased.
Esomeprazole was introduced to the market in the mid-1990s, and as a proton pump inhibitor (PPI), it is still in use today. In this issue, Dr. Nadea discusses the benefits of Nexium® (esomeprazole) and its potential risks and side effects.
A recent study published infound that the risk of acid reflux and ulcers was lower when esomeprazole was taken by mouth or directly through the esophagus. The risk of ulcers in patients who take Nexium® for a long time may be higher than that seen in people who do not take esomeprazole.
Nadea is the author of several books includingThe Long Formulary: How Esomeprazole Works, and is the executive director of theAmerican Gastroenterological Association.
She is a board-certified gastroenterologist.
This issue ofprovides the first and most recent review of the latest research in the treatment of reflux and ulcers associated with the condition. The research has been extensive, with many articles and reviews. Nadea is an expert in the fields of gastrointestinal diseases and is a leader in the development and practice of medicine for patients who have GERD.
In theNadea discusses the role of the gastroesophageal reflux disease (GERD) treatment. The treatment has several indications and can be used to treat a variety of conditions. She has been writing about the treatment of GERD for decades. The main indication for GERD is heartburn, and the symptoms of GERD may include burning, acid reflux and ulcers. The condition can be life-threatening, and a number of treatment options are available.
Nadea is also the author ofHeartburn and Other Gastrointestinal Diarrhea: A Review of the Literature, as well as a contributor toAmerican Journal of Gastroenterology, where she has written about the treatment of gastroesophageal reflux disease (GERD).
, is available online at.
The Long Formulary, an article on the latest developments in the treatment of acid reflux. The article is published in the.
Her primary interest is in the field of gastroesophageal reflux disease (GERD). Her primary research area is stomach acid reflux disease (SAR).
She has received grants from the AstraZeneca PLC and the American Heart Association. She is a co-author of
She is a consultant and author on other publications.
She is a member of the American Gastroenterological Association’s GERD Association and has been a speaker for the American Gastroenterological Association.
She is a past chair of the American Heart Association, and the GERD Association Scientific Advisory Committee.
Nadea has an additional issue to discuss today. She was diagnosed with GERD in 2015. In her recent column, she writes “Esomeprazole (esomeprazole) is used to treat reflux and ulcers. There is no specific treatment for GERD, and it is not recommended for patients who have reflux or ulcers. The only other available treatment option is Nexium®. The drug is not as effective as esomeprazole and it may be better for people with GERD who have symptoms of GERD or an underlying medical condition that is not treated appropriately.”Nephrology.Nexium 24HR Once Daily Dosing Tablets provide lasting relief from frequent heartburn and acid reflux.
Nexium 24HR 20mg esomeprazole tablets are for the lasting symptomatic relief of frequent heartburn, acid regurgitation and other symptoms associated with gastro-oesophageal reflux
Carefully read the enclosed Consumer Medicine Information before use.
AUST R NUMBER:231439
Lactose
INGREDIENTS:Each tablet contains: Esomeprazole 20mg (as Magnesium Trihydrate).
Do not use:- for children under 18 years of age.- if allergic to esomeprazole.- if allergic to any other proton pump inhibitor (omeprazole, rabeprazole, lansoprazole, pantoprazole).- if you are taking antiretroviral medicines, such as atazanavir.- if you are taking cilostazol a medicine used to treat pain and/or cramping in the lower leg (or arms) due to inadequate blood flow to the muscles.- if you are breastfeeding or intend to breastfeed.- -f you are experiencing weight loss, persistent regurgitation of food or vomiting, difficulty swallowing or symptoms of gastro-intestinal bleeding, except on medical advice- if you are pregnant or intend to become pregnant except on the advice of a doctor or pharmacist- if the expiry date printed on the pack has passed. Ask your pharmacist or doctor before use if you:- have or ever have had serious liver disease.- are taking digoxin (a medicine used to treat heart problems).- are taking ketoconazole (a medicine used to treat fungal infections)- are taking clopidogrel or warfarin (medicines used to stop the blood clotting)- are taking other medicines regularlyThis preparation is for the relief of minor and temporary ailments and should be used strictly as directed. Do not use for any purpose other than what is specified on the pack, except on doctor's advice. Keep to recommended dose. If an overdose is taken or suspected telephone your doctor or the Poisons Information Centre (Australia 13 11 26, or New Zealand 0800 764 766) or go to the Accident and Emergency department at your nearest hospital. Tell your pharmacist or doctor if you do not feel well, if new or additional symptoms occur while you are taking Nexium 24HR Once Daily Dosing.
ONLINE MANDATORY STATEMENT:Always read the label and follow the directions for use.
Puerto Rico, US
MRL:No
Sun Pharmaceutical
Lactated forms ofNexium 24HR Once Daily Dosing Tabletsnspi.
Stade de France Pharmacy